Overview

A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function

Status:
COMPLETED
Trial end date:
2024-11-27
Target enrollment:
Participant gender:
Summary
NNC0519-0130 is a new medicine to improve the treatment options for people living with type 2 diabetes and people with overweight. In this study one dose of NNC0519-0130 will be given and blood levels of NNC0519-0130 will be compared between people with reduced kidney function and people with normal kidney function. The study will last up to 52 days including a screening phase of up to 28 days prior to dosing.
Phase:
PHASE1
Details
Lead Sponsor:
Novo Nordisk A/S